Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980647 | 0.84 | — | — | |
| SCHEMBL2633896 | 0.79 | TSHR (0.39) | DPP4ALDH1A1TSHRMAPK1ANPEP | |
| SCHEMBL172567 | 0.79 | ALDH1A1 (0.39) | DPP4ALDH1A1TSHRMAPK1ANPEP | |
| SCHEMBL13995117 | 0.79 | ALDH1A1 (0.39) | DPP4ALDH1A1TSHRMAPK1ANPEP | |
| SCHEMBL13995101 | 0.77 | EPHX1 (0.41) | DPP4ALDH1A1TSHRMAPK1 | |
| SCHEMBL13995102 | 0.77 | EPHX1 (0.41) | DPP4ALDH1A1TSHRMAPK1 | |
| SCHEMBL24838517 | 0.77 | DPP4 (0.44) | DPP4CPN1CPB2SLC6A2SLC6A4 | |
| SCHEMBL2465728 | 0.77 | DPP4 (0.44) | DPP4CPN1CPB2SLC6A2SLC6A4 | |
| SCHEMBL4290459 | 0.75 | DPP4 (0.46) | DPP4CPN1CPB2ANPEPERAP2 | |
| SCHEMBL22798913 | 0.74 | DPP4 (0.42) | DPP4CPN1CPB2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1948663-B1 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-1948663-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048066-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-0922048-A1 | PROCESS FOR THE PREPARATION OF N- (1-?n BUTYL-4-PIPERIDYL)METHYL] -3,4-DIHYDRO -2H- 1,3] OXAZINO 3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998007728-A1 | PROCESS FOR THE PREPARATION OF N-[(1-nBUTYL-4-PIPERIDYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS | SMITHKLINE BEECHAM PLC (GB) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | CSNK1A1, CSNK2A1, CSNK2A2 | DPP4 1268/4885ALDH1A1 4176/4885TSHR 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.